QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mourlevat, S. Articles by Michel, P. P. Search for Related Content PubMed PubMed Citation Articles by Mourlevat, S. Articles by Michel, P. P.

Prevention of Dopaminergic Neuronal Death by Cyclic AMP in Mixed Neuronal/Glial Mesencephalic Cultures Requires the Repression of Presumptive Astrocytes

Institut National de la Santé et de la Recherche Médicale U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France

Cyclic AMP-elevating agents are highly effective in preventing the loss of dopaminergic neurons that occurs spontaneously in neuronal-glial mesencephalic cultures. We demonstrate here that cAMP causes a concomitant decline in the number of dividing non-neuronal cells, suggesting that inhibition of proliferation contributes to neuroprotection. Consistent with this hypothesis, a transient treatment with the antimitotic cytosine arabinoside, at concentrations that induce long-term repression of glial cell proliferation, mimicked the neuroprotective action of cAMP and also obviated the need for the cyclic nucleotide. Treatment with cAMP-elevating agents reduced the population of OX-42–positive microglial cells and the number of immature astrocytes expressing vimentin and low levels of the astrocytic marker glial fibrillary acidic protein. The effect on the immature astrocytes, however, seemed essential for neuroprotection. Ciliary neurotrophic factor and leukemia inhibitory factor, which stimulate astrocyte differentiation without reducing cell proliferation, failed to reproduce the protective effects of the cyclic nucleotide. Cyclic AMP did not operate by counteracting the action of the astrocyte mitogen epidermal growth factor or by reducing activation of the mitogen-activated protein kinase signaling pathway. The neuroprotective and antiproliferative actions of cAMP, however, were closely mimicked by olomoucine and roscovitine, potent inhibitors of the cyclin-dependent kinase CDK1 that are structurally related to cAMP. Measurement of CDK1 activity confirmed that neuroprotection was closely correlated with inhibition of this kinase by cAMP. In summary, neuroprotection of mesencephalic dopaminergic neurons by cAMP most probably requires the repression of presumptive astrocytes through inhibition of CDK1.

Received March 31, 2003; accepted May 14, 2003.

Address correspondence to: Dr. Patrick Michel, INSERM 289, Experimental Neurology and Therapeutics, Bâtiment Pharmacie, Hôpital de la Salpêtrière, 47 bd de l'Hôpital, 75013 Paris, France. E-mail: ppmichel{at}ccr.jussieu.fr

This article has been cited by other articles:

				S. Guerreiro, D. Toulorge, E. Hirsch, M. Marien, P. Sokoloff, and P. P. Michel Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels Mol. Pharmacol., October 1, 2008; 74(4): 980 - 989. [Abstract] [Full Text] [PDF]

				B. Salthun-Lassalle, S. Traver, E. C. Hirsch, and P. P. Michel Substance P, Neurokinins A and B, and Synthetic Tachykinin Peptides Protect Mesencephalic Dopaminergic Neurons in Culture via an Activity-Dependent Mechanism Mol. Pharmacol., November 1, 2005; 68(5): 1214 - 1224. [Abstract] [Full Text] [PDF]

				B. Salthun-Lassalle, E. C. Hirsch, J. Wolfart, M. Ruberg, and P. P. Michel Rescue of Mesencephalic Dopaminergic Neurons in Culture by Low-Level Stimulation of Voltage-Gated Sodium Channels J. Neurosci., June 30, 2004; 24(26): 5922 - 5930. [Abstract] [Full Text] [PDF]